PPV safe for irradiated uveal melanoma

Article

Pars plana vitrectomy is safe to use on patients with plaque-irradiated uveal melanoma.

Pars plana vitrectomy is safe to use on patients with plaque-irradiated uveal melanoma, according to a study in the Archives of Ophthalmology.

The retrospective case series, headed by Dr Alok S. Bansal, Department of Immunology, St Helier Hospital, Carshalton, Surrey, UK, included 47 eyes of 47 patients with plaque-irradiated posterior uveal melanoma who underwent PPV for vitreous haemorrhage.

The primary outcome measures included rates of intraocular melanoma dissemination, extrascleral extension of melanoma, local melanoma recurrence and systemic melanoma metastasis after PPV.

No cases of intraocular melanoma dissemination or extrascleral extension of melanoma were found. Local choroidal melanoma recurrence was found in one patient and was successfully managed with transpupillary thermotherapy.

After a mean interval of five years after plaque radiotherapy, four patients experienced systemic melanoma metastasis. The management of vitreous haemorrhage using PPV is safe and doesn’t increase the risk of intraocular, local, orbital or systemic dissemination of the tumour in patients with uveal melanoma.

To read the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.